The 36-month beta value for PRME is at 1.88. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for PRME is 50.89M, and currently, shorts hold a 30.97% of that float. The average trading volume for PRME on December 13, 2024 was 1.67M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PRME) stock’s latest price update
Prime Medicine Inc (NASDAQ: PRME) has seen a decline in its stock price by -4.75 in relation to its previous close of 3.16. However, the company has experienced a 1.35% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-26 that Prime Medicine’s proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME’s pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson’s Disease, with clinical data expected in 2025. PRME’s strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies.
PRME’s Market Performance
Prime Medicine Inc (PRME) has experienced a 1.35% rise in stock performance for the past week, with a -30.32% drop in the past month, and a -26.41% drop in the past quarter. The volatility ratio for the week is 8.21%, and the volatility levels for the past 30 days are at 8.32% for PRME. The simple moving average for the past 20 days is -6.42% for PRME’s stock, with a -41.46% simple moving average for the past 200 days.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with JMP Securities repeating the rating for PRME by listing it as a “Mkt Outperform.” The predicted price for PRME in the upcoming period, according to JMP Securities is $10 based on the research report published on December 10, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRME reach a price target of $10. The rating they have provided for PRME stocks is “Buy” according to the report published on May 20th, 2024.
Citigroup gave a rating of “Buy” to PRME, setting the target price at $10 in the report published on May 16th of the current year.
PRME Trading at -18.00% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.47% of loss for the given period.
Volatility was left at 8.32%, however, over the last 30 days, the volatility rate increased by 8.21%, as shares sank -23.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.24% lower at present.
During the last 5 trading sessions, PRME rose by +1.35%, which changed the moving average for the period of 200-days by -67.21% in comparison to the 20-day moving average, which settled at $3.22. In addition, Prime Medicine Inc saw -66.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRME starting from NELSEN ROBERT, who purchase 3,200,000 shares at the price of $6.25 back on Feb 15 ’24. After this action, NELSEN ROBERT now owns 3,200,000 shares of Prime Medicine Inc, valued at $20,000,000 using the latest closing price.
ARCH Venture Partners XII, LLC, the 10% Owner of Prime Medicine Inc, purchase 3,200,000 shares at $6.25 during a trade that took place back on Feb 15 ’24, which means that ARCH Venture Partners XII, LLC is holding 3,200,000 shares at $20,000,000 based on the most recent closing price.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -5.87 for the present operating margin
- 0.98 for the gross margin
The net margin for Prime Medicine Inc stands at -5.68. The total capital return value is set at -0.77. Equity return is now at value -114.35, with -76.67 for asset returns.
Currently, EBITDA for the company is -193.76 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 8.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.50.
Conclusion
In conclusion, Prime Medicine Inc (PRME) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
